|
pubmed:abstractText |
Risperidone is one of a number of 'atypical antipsychotics' which are currently being marketed for the treatment of those with schizophrenia, largely on the basis of claims of improved tolerability and effectiveness compared to much cheaper conventional antipsychotics. The efficacy of risperidone has already been compared to conventional drugs, but it remains unclear how risperidone compares with other atypical antipsychotic drugs such as clozapine.
|
|
pubmed:affiliation |
NHS Centre for Reviews and Dissemination, University of York, NHS Centre for Reviews and Dissemination, University of York, York, North Yorkshire, UK, YO10 5DD. smg5@york.ac.uk
|
